Navigation Links
Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
Date:5/17/2012

ISELIN, N.J., May 17, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a trial was conducted at the Duke Clinical Research Unit of Duke University and the principal investigator was John Sundy, MD, PhD, an expert and key opinion leader in the treatment of gout. The trial was designed to assess the safety and efficacy of levotofisopam as a uric acid-lowering agent in patients with gout.

The trial enrolled 13 patients in an open label study with patients confined in the Duke facility.  The study enrolled patients with screening serum urate between 8 and 12 mg/dL. Subjects received a single dose of 50 mg on days 1 and 7 and 50 mg TID on days 2 through 6.  Levotofisopam was well tolerated. The mean reduction in serum urate was over 45%. All 13 patients were responders, and demonstrated a serum urate level of less than 6 mg/dL on day 7. Seven subjects achieved a serum urate level less than 4 mg/dL on day 7. Additionally there was an increase in the fractional excretion of urate, confirming the compound's mechanism of action as a uricosuric agent that enhances urate excretion by the kidneys. 

Commenting on the results of this Phase 2a trial, the principal investigator Dr. John Sundy said, "monotherapy with levotofisopam was well tolerated and induced clinically important reductions in serum urate levels in all patients studied. These results support further development of levotofisopam for treating hyperuricemia in patients with gout."

This trial follows two prior phase 1 clinical studies conducted by Vela Pharmaceuticals (merged with Pharmos in October 2006). In these studies, conducted in healthy volunteers in the United Kingdom and The Netherlands, levotofisopam treatment was generally well tolerated and was associated with
'/>"/>

SOURCE Pharmos Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmos Corporation Reports First Quarter 2012 Results
2. Pharmos Corporation Reports 2011 Fourth Quarter and Full Year Results
3. Pharmos Corporation Reports 2011 Second Quarter Results
4. Pharmos Corporation Reports 2010 Third Quarter Results
5. Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
6. Pharmos Corporation Reports 2009 Third Quarter Results
7. Pharmos Issues Business Update on Dextofisopam Trial and Financing
8. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
9. Henry Schein Ranks #303 In 2012 FORTUNE 500® Ranking Of Americas Largest Corporations
10. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
11. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... 16, 2014 Eight finalists, all representing outstanding ... present their proposals for a chance to compete for ... Sheikh Zayed Institute Second Annual Pediatric Surgical Innovation Symposium ... on Friday, Oct. 24, 2014. Selected from ... the US and internationally, the finalists are: ...
(Date:10/16/2014)... 16, 2014 Curtis & Coulter LLC, a ... away from hosting their co-located Bioequivalence: Intersection Between ... Formulation Innovations Summit taking place on November 5-6 ... November,s events are specifically designed ... the bioequivalence testing process, as well as optimizing formulation ...
(Date:10/16/2014)... 2014  Personna Industrial, the world,s leading manufacturer of ... and safety systems will be exhibiting at the MD&M ... on October 29-30th. Personna Industrial,s booth is #847. MD&M ... for medical device design and manufacturing professionals. The MD&M ... and applications that are redefining the medical device manufacturing ...
Breaking Medicine Technology:Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2Personna Industrial Exhibiting Among Top Suppliers To Medical Industry At MD&M Minneapolis 2
... public health, and regulatory highlights for this week from ... document is designed for credentialed journalists. Release dates and ... 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... any regulatory or enforcement actions due to legal limitations. ...
... YORK,  June 6, 2011 Aeolus Pharmaceuticals, Inc. (OTCQB: ... is available for on-demand viewing. LINK: ... button. Aeolus Pharmaceuticals, presentation will be available ... the "virtual trade booth" for the next three weeks. ...
Cached Medicine Technology:FDA News & Notes - Week of June 6, 2011 2Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2
(Date:10/18/2014)... October 19, 2014 Mercy’s student mentoring ... report on programs that help college students succeed. ... software and services, published the recent paper, “Retention and ... and Mercy is one of six higher education institutions ... fall to fall retention rates for first-time, full-time students ...
(Date:10/18/2014)... (PRWEB) October 19, 2014 Recently, BamboofloorChina.com, one ... market, has added a new assortment of bamboo floorings ... offering huge price cuts for worldwide clients now, up to ... of useful and durable items for sale now; most of ... decades. Clients can find more than 100 different kinds of ...
(Date:10/18/2014)... October 2014 All humans have a natural opioid system ... ECNP Congress in Berlin, has found that the opioid ... normal healthy volunteers. The work was carried out by ... and was funded by the Medical Research Council. This ... Neuropsychopharmacology congress in Berlin., Gambling is a widespread behaviour ...
(Date:10/18/2014)... NY (PRWEB) October 18, 2014 Ticket Down is ... prices have eased considerably for this year's World Series. ... in the World Series this year. This determined team has ... The San Francisco Giants have had better luck in terms of ... 2010, 1954, 1933, 1922, 1921 and 1905. This team ...
(Date:10/18/2014)... 18, 2014 Market Research ... Industry, 2009-2019 is a professional and in-depth ... Chondroitin sulfate industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Chondroitin sulfate listing their product ...
Breaking Medicine News(10 mins):Health News:Mercy’s PACT Student Mentoring Program Recognized for Helping College Students Succeed 2Health News:Brand New Bamboo Floorings Now Unveiled By BamboofloorChina.com, A Distinguished Supplier In The Market 2Health News:Pathological gambling is associated with altered opioid system in the brain: Reduced feeling of euphoria when compared to healthy volunteers 2Health News:2014 World Series Tickets: Giants vs. Royals World Series Ticket Prices Have Eased Substantially 2Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 2Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 3Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 4
... Israel, Nov. 29 Elbit Imaging Ltd.,(TASE, Nasdaq: ... November,28, 2007, InSightec Ltd. ("InSightec"), a subsidiary of ... an agreement for an internal,round of financing in ... existing,investors, namely: Elbit Ultrasound (Netherlands) B.V., a fully ...
... Satellite Newsfeed Notification ... Friday, 11/30, WASHINGTON, Nov. 29 , ... more than 19,million Americans. Despite its prevalence, depression ... is a,first-of-its-kind study examining the statistical relationship between ...
... benefit for the female hormone , THURSDAY, Nov. 29 ... which is often given with estrogen in hormone replacement ... U.S. researchers say. , They conducted tests on female ... come to this conclusion. , Treatment with estrogen blocked ...
... Week to Experience the, World,s Most Advanced Laparoscopic Surgery ... ... Congress, CLEVELAND, Ohio, November 29 Simbionix unveiled the,latest module ... Global Congress of Minimally Invasive Gynecology., The LAP Mentor(TM) multidisciplinary ...
... Utah, Nov. 29 Nutraceutical,International Corporation (Nasdaq: NUTR ... and year ended September 30, 2007., Net sales ... to $35.7 million for the same quarter of fiscal ... or $0.23 diluted earnings per,share, compared to net income ...
... 29 InSightec Ltd. today,reported that it has closed ... existing investors: Elbit Imaging Ltd. (Nasdaq: EMITF ), ... Company,(NYSE: GE ), MediTech Advisors LLC ("MTA"), a ... managers of the company., The investment will take ...
Cached Medicine News:Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 2Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 3Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 4Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 2Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 3Health News:Progesterone Won't Shield Women Against Alzheimer's 2Health News:Gynecologists Get First Hands-On Experience With Simbionix LAP Mentor(TM) 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 3Health News:Nutraceutical Reports 2007 Fiscal Year End Results 4Health News:Nutraceutical Reports 2007 Fiscal Year End Results 5Health News:Nutraceutical Reports 2007 Fiscal Year End Results 6Health News:InSightec Ltd. Announces US$30 Million Investment Round 2Health News:InSightec Ltd. Announces US$30 Million Investment Round 3
Digital Ultrasonic Diagnostic Imaging System...
...
Pefakit PiCT DxS Diluent for Determination of Total Heparin...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Medicine Products: